The LEQVIO® Service Center provides simple, reliable, and supportive solutions to help your patients start and stay on LEQVIO.

Person with headset

9 out of 10 users said they
were satisfied or extremely
satisfied
when engaging with the LEQVIO Service Center

Enroll today to get any of the following support offerings:

Choose the option that works best for you and your patient

In-office Administration

Prefer to administer LEQVIO in your office?

printer icon

Download the Start Form and fax it to 877-537-8468 to receive support

Download Start Form

OR

registration icon

Register for the Service Center Portal to receive support and submit requests online

Visit Service Center Portal

Out-of-office Administration

Prefer to refer your patient to an alternate site of care (ASOC) for administration?

Site of care icon

Use our locator tool to find an ASOC that is convenient for you and your patient

Visit ASOC Locator Tool

Most popular resources

Reference: Data on file. Novartis Pharmaceuticals Corp; 2023.

Explore Coverage &
Affordability

IMPORTANT SAFETY INFORMATION
AND INDICATION

Expand Collapse

IMPORTANT SAFETY INFORMATION

LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included angioedema. Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

Please click here for LEQVIO full Prescribing Information.